The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Pulmotech MAA Market During The 2026–2030 Period?

Historically, this growth was primarily driven by a surge in pulmonary embolism cases, the expansion of nuclear medicine departments within healthcare facilities, the widespread availability of technetium-based radiopharmaceuticals, an increase in diagnostic imaging procedures, and the growing clinical adoption of lung scintigraphy.

During the forecast period, expansion is anticipated due to an escalating need for timely and precise pulmonary diagnostics, coupled with increased capital expenditure in nuclear medicine infrastructure, broader clinical investigation utilizing radiotracers, a heightened emphasis on individualized diagnostic imaging, and advancements in imaging agent technology. Key trends for the forecast period encompass a growing uptake of sophisticated lung perfusion imaging agents, an increased reliance on nuclear medicine for pulmonary diagnostics, a heightened requirement for accurate pulmonary embolism identification, the broadening scope of radiopharmaceutical clinical applications, and a stronger emphasis on ensuring imaging accuracy and patient safety.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20329&type=smp

What Key Growth Drivers Are Influencing The Pulmotech MAA Market?

The escalating occurrence of respiratory conditions is projected to boost the pulmotech MAA market. These conditions encompass a wide array of ailments affecting the lungs and other respiratory components like airways and muscles. The rising prevalence of respiratory diseases is influenced by factors such as environmental pollution, lifestyle choices, an aging populace, and enhancements in diagnostic techniques. Pulmotech MAA serves in the diagnosis and management of long-term respiratory issues by facilitating pulmonary imaging to evaluate regional lung function and identify potential anomalies like perfusion deficits. As an illustration, in June 2024, the Australian Institute of Health and Welfare, an Australia-based health and welfare agency, reported that approximately 8.5 million people in Australia, representing 34% of the population, were estimated to be living with chronic respiratory conditions. This figure includes about 2.8 million individuals, or 11% of the population, with asthma, and 638,000 people, or 2.5% of the population, suffering from chronic obstructive pulmonary disease (COPD). Consequently, the increased incidence of respiratory diseases is fueling the pulmotech MAA market. The increasing prevalence of chronic diseases is set to drive the expansion of the pulmotech MAA market. Chronic diseases are defined as health conditions that persist for prolonged periods, often spanning years or a lifetime. This rise in chronic diseases is primarily attributed to shifts in lifestyle, an aging global population, and environmental factors. Pulmotech MAA offers significant utility in managing the escalating burden of chronic diseases, particularly those impacting the respiratory system. It is employed in the assessment and treatment of these conditions by enabling precise imaging of pulmonary perfusion, assisting in the diagnosis of ailments such as pulmonary embolism, and monitoring various lung disorders. For instance, in April 2025, the National Center for Health Statistics (NCHS) under the Centers for Disease Control and Prevention (CDC), a US-based source of health statistics, highlighted an upward trend in chronic diseases, notably among young and midlife adults. Among young adults, obesity prevalence saw an increase from 27.3% in 2023, and depression rose from 25.0%, alongside noted increases in diabetes and chronic kidney disease in midlife adults. Thus, the growing prevalence of chronic diseases is anticipated to spur the growth of the pulmotech MAA market.

How Is The Pulmotech MAA Market Distributed Across Key Segments?

The pulmotech maa market covered in this report is segmented –

1) By Application: Pulmonary Embolism Diagnosis, Preoperative Assessment, Lung Transplant Viability, Chronic Respiratory Disease Evaluation, Clinical Research

2) By Distribution Channel: Direct Sales, Distributors, Online Platforms

3) By End-User: Hospitals, Research Institutions, Diagnostic Imaging Centers

Which Companies Are Influencing The Pulmotech MAA Market?

Major companies operating in the pulmotech maa market are Curium Pharma

Access The Complete Pulmotech MAA Market Report:

https://www.thebusinessresearchcompany.com/report/pulmotech-maa-global-market-report

Which Geographic Region Represents The Largest Pulmotech MAA Market Share?

North America was the largest region in the pulmotech MAA market in 2025. The regions covered in the pulmotech maa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model